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ABSTRACT
Objective Receptor- interacting protein kinase 3 (RIPK3) 
is a key player in necroptosis execution and an emerging 
metabolic regulator, whose contribution to non- alcoholic 
fatty liver disease (NAFLD) is controversial. We aimed to 
clarify the impact of RIPK3 signalling in the pathogenesis 
of human and experimental NAFLD.
Design RIPK3 levels were evaluated in two large 
independent cohorts of patients with biopsy proven 
NAFLD diagnosis and correlated with clinical and 
biochemical parameters. Wild- type (WT) or Ripk3- 
deficient (Ripk3−/−) mice were fed a choline- deficient 
L- amino acid- defined diet (CDAA) or an isocaloric control 
diet for 32 and 66 weeks.
Results RIPK3 increased in patients with non- alcoholic 
steatohepatitis (NASH) in both cohorts, correlating with 
hepatic inflammation and fibrosis. Accordingly, Ripk3 
deficiency ameliorated CDAA- induced inflammation and 
fibrosis in mice at both 32 and 66 weeks. WT mice on 
the CDAA diet for 66 weeks developed preneoplastic 
nodules and displayed increased hepatocellular 
proliferation, which were reduced in Ripk3−/− mice. 
Furthermore, Ripk3 deficiency hampered tumourigenesis. 
Intriguingly, Ripk3−/− mice displayed increased body 
weight gain, while lipidomics showed that deletion 
of Ripk3 shifted hepatic lipid profiles. Peroxisome 
proliferator- activated receptor γ (PPARγ) was increased 
in Ripk3−/− mice and negatively correlated with hepatic 
RIPK3 in patients with NAFLD. Mechanistic studies 
established a functional link between RIPK3 and PPARγ 
in controlling fat deposition and fibrosis.
Conclusion Hepatic RIPK3 correlates with NAFLD 
severity in humans and mice, playing a key role in 
managing liver metabolism, damage, inflammation, 
fibrosis and carcinogenesis. Targeting RIPK3 and its 
intricate signalling arises as a novel promising approach 
to treat NASH and arrest disease progression.
INTRODUCTION
Non- alcoholic fatty liver disease (NAFLD) is the most 
common chronic liver disease in Western countries 
and its prevalence and incidence is increasing due 
to its strong association with obesity and metabolic 
syndrome, and the lack of pharmacological therapies.1 
NAFLD encompasses a spectrum ranging from hepatic 
steatosis to non- alcoholic steatohepatitis (NASH), ulti-
mately leading to liver cirrhosis and/or cancer.2 In turn, 
liver cancer displays a high mortality rate, ranking as 
Significance of this study
What is already known on this subject?
 ► Non- alcoholic steatohepatitis is already a 
relevant aetiology of cancer- related liver 
transplantation and the non- alcoholic fatty 
liver disease (NAFLD) mortality is alarmingly 
increasing.
 ► Receptor- interacting protein kinase 3 (RIPK3)- 
dependent necroptosis is activated in the 
liver of patients with NAFLD, but its specific 
contribution to disease pathogenesis remains 
controversial.
 ► Besides its well- established role in necroptosis 
execution, RIPK3- dependent signalling is arising 
as key player in metabolic reprogramming.
What are the new findings?
 ► Hepatic RIPK3 levels positively correlate with 
NAFLD severity in humans, emphasising the 
role of RIPK3 signalling in regulating NAFLD 
progression.
 ► RIPK3 deficiency ameliorates disease severity 
induced by mid- term and long- term choline- 
deficient L- amino acid- defined diet diet.
 ► RIPK3 deficiency dampens signalling pathways 
involved in tumourigenesis.
 ► RIPK3 differentially controls liver steatosis 
versus inflammation during hypercaloric diet 
feeding.
 ► Deletion of RIPK3 impacts on hepatic lipidome 
and upregulates peroxisome proliferator- 
activated receptor γ.
How might it impact on clinical practice in the 
foreseeable future?
 ► These results unveil a novel metabolic role of 
RIPK3, whose targeting might arrest NAFLD 
progression towards hepatocellular carcinoma.
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the sixth most common cancer and the fourth most deadly world-
wide.3 In the USA, NASH is already the second leading aetiology of 
cancer- related liver transplantation4 5 and the NAFLD mortality is 
predicted to increase by 178% between 2015 and 2030.6
Hepatocellular carcinoma (HCC), the most common primary 
liver cancer, arises almost exclusively in the setting of chronic hepatic 
inflammation and fibrosis. In turn, cell death represents a dominant 
trigger of inflammation and fibrosis, thus contributing to multiple 
hallmark features of cancer.7 In addition, chronic cell death in non- 
transformed hepatocytes increases cell turnover and selects for clones 
better adapted to survive and proliferate, thus driving tumour devel-
opment.8 Still, knowledge on the association between liver cancer 
and chronic cell death and inflammation has not yet identified phar-
macological targets that could alter the progression of chronic liver 
disease towards fibrosis and cancer.
Necroptosis represents a regulated necrotic cell death pathway 
activated downstream of death receptor stimulation and depen-
dent on receptor- interacting protein kinase 3 (RIPK3) activity. On 
activation, RIPK3 phosphorylates mixed lineage kinase domain- 
like protein (MLKL), which plays a critical, non- redundant role 
in executing necroptosis.9 10 Necroptosis is highly immunogenic 
and, when sustained, may contribute to chronic inflammation 
and carcinogenesis.11 In addition, emerging evidence suggests that 
necroptosis- associated signalling could play a role in metabolic 
reprograming, including lipid metabolism and mitochondrial respi-
ration,12–15 which are key for progression of chronic liver disease and 
carcinogenesis.
We and others have shown that RIPK3- dependent hepatocyte 
necroptosis is activated in patients with NAFLD and experimental 
NASH,16–18 but the specific contribution of RIPK3- dependent signal-
ling in NAFLD pathogenesis remains controversial. For instance, 
activation of necroptosis was shown to contribute to liver damage, 
fibrosis, oxidative stress and inflammation in methionine- deficient 
and choline- deficient diet- induced NASH in mice,16 17 while in 
high- fat diet (HFD) RIPK3 deficiency exacerbates liver steatosis 
and inflammation, as well as circulating insulin/glucose levels 
induced.18 19 Similarly, RIPK3 was suggested to inhibit hepatocar-
cinogenesis in a genetic model of chronic hepatic inflammation,20 
while necroptosis- associated hepatic cytokine microenvironment 
impinges on epigenetics triggering cholangiocarcinoma develop-
ment from ontogenically transformed hepatocytes.11 In this study, 
we dissected the impact of RIPK3 signalling in lipid metabolism, 
steatosis, inflammation, fibrosis and carcinogenesis associated with 
NAFLD, by using human samples, mechanistic in vitro studies and an 
experimental model that recapitulates a broad spectrum of NAFLD 
and its sequel to HCC. We show that hepatic RIPK3 levels correlate 
with NAFLD severity in large independent human cohorts, empha-
sising the role of RIPK3- signalling in regulating NAFLD progression. 
Furthermore, RIPK3 differentially controls steatosis versus inflam-
mation in choline- deficient L- amino acid- defined (CDAA)- fed mice, 
likely through peroxisome proliferator- activated receptor γ (PPARγ) 
modulation, suggesting that these events are dissociated in NAFLD 
progression to HCC.
MATERIALS AND METHODS
Additional materials and methods are included in online supple-
mental information.
Patient cohorts
NAFLD liver specimens were prospectively and sequentially collected 
from two independent cohorts of patients with biopsy- proven diag-
nosis of NAFLD (cohort A: n=71; cohort B: n=146). See online 
supplemental materials and methods for details.
Animals and diets
Male C57BL/6 mice aged 7–8 weeks wild- type (WT) or Ripk3- 
deficient mice (Ripk3−/−)21 from the same genetic background were 
fed either a choline- deficient L- amino acid- defined (CDAA) diet 
(Envigo, Madison, USA) or a control choline- sufficient L- amino 
acid- defined (CSAA) diet for 32 or 66 weeks, and histopathology, 
serum analysis, glucose tolerance tests, liver lipidomics and gene 
expression analysis were performed as described in online supple-
mental materials and methods.
Quantitative RT-PCR
Total RNA was purified from frozen human liver tissue and extracted 
from animal liver and epididymal white adipose samples using the 
TRIzol reagent (ThermoFisher, Waltham, Massachusetts, USA). The 
mRNA level of human selected genes was normalised for the level of 
glyceraldehyde- 3- phosphate dehydrogenase (GAPDH). In turn, rela-
tive amounts of selected mouse genes were calculated based on the 
standard curve normalised to the level of hypoxanthine phosphori-
bosyltransferase (Hrpt) and expressed as fold change from CSAA WT 
mice at each respective time- point, except for the microarray valida-
tion where β-actin was used as reference gene and results expressed 
as fold change from non- tumorous (NT) tissue of CDAA WT mice. 
See online supplemental materials and methods for details.
Mouse liver cancer genes array
Differential gene expression in NT tissue from CDAA- fed WT 
mice versus NT from CDAA- fed Ripk3−/− mice or tissue enriched 
in preneoplastic nodules from CDAA- fed WT or Ripk3−/− mice 
was evaluated using a RT² Profiler Mouse Liver Cancer PCR Array 
(PAMM- 133Z, Qiagen, Maryland, USA) according to the manufac-
turer’s instructions and as described in online supplemental materials 
and methods.
Cell culture and immunoblotting
Total protein extraction and immunoblotting were performed as 
previously described.22 Immunoblotting and cell culture and treat-
ments are detailed in online supplemental materials and methods.
Statistical analysis
Regular statistical analysis was performed with GraphPad Prism 7 
software (GraphPad Software, San Diego, California, USA). The 
Shapiro- Wilk test was used for testing the normality of data. Student’s 
t- test was applied when two groups were analysed. According to 
normality of values distribution, analysis of variance followed by 
Tukey’s multiple comparison or Krustal- Wallis followed by Dunn’s 
multiple comparison test were performed if three or more groups 
were compared. Association between two variables was assessed by 
Pearson’s or Spearman’s correlation coefficient for normally and 
non- normally distributed data, respectively. Values of p<0.05 were 
considered statistically significant.
RESULTS
Hepatic RIPK3 levels are increased in patients with NASH and 
correlate with disease severity
RIPK3 levels were evaluated in two large independent cohorts 
of patients, with clinical and biopsy- proven diagnosis of NAFLD 
and correlated with clinical and biochemical parameters.
In cohort A, similar to data already reported for RIPK1 and 
MLKL,13 serum RIPK3 protein levels were significantly increased 
in patients with active disease (histological activity score ≥2 vs 
<2) (figure 1A), likely mirroring necro- inflammatory activity. 
Hepatic RIPK3 mRNA levels were also increased in patients with 
NAFLD, while the expression of other mediators of necroptosis 
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Figure 1 Receptor- interacting protein kinase 3 (RIPK3) levels are increased in patients with non- alcoholic steatohepatitis (NASH) and correlate with 
disease severity. (A) RIPK3 protein levels in the serum of cohort A patients with non- alcoholic fatty liver disease (NAFLD), divided according to the 
histological activity score (<2, n=8 or ≥2 n=26), measured through ELISA. (B) Quantitative RT- PCR analysis of hepatic RIPK1, RIPK3, mixed lineage 
kinase domain- like protein (MLKL) and caspase- 3 (CASP- 3) in the liver of cohort A patients with NAFLD (n=71). (C) Correlations of hepatic mRNA 
levels of RIPK3 with tumour necrosis factor (TNF), interleukin- 1β (IL- 1β), NACHT, LRR and PYD domains- containing protein 3 (NLRP3), collagen1α1 
(COL1α1) or MLKL in patients of cohort A. (D) Representative RIPK3 immunofluorescence (red) in liver sections from cohort B patients with NAFLD. 
Scale bar=100 µm. Histograms show the quantification of RIPK3 levels assessed by immunofluorescence according to NAFLD activity score (NAS) 
score, fibrosis score and PNPLA3 genotype (n=146). (E) Correlations of hepatic RIPK3 mRNA expression with serum levels of alanine transaminase 
(ALT), aspartate transaminase (AST) and γ-glutamyltranspeptidase (GGT), before (red) and 1 year after (blue) bariatric surgery in patients from cohort 
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and apoptosis were not altered between control, non- alcoholic 
fatty liver and NASH (figure 1B). Accordingly, hepatic RIPK3 
mRNA levels positively correlated with the expression of several 
pro- inflammatory markers increased in the liver of patients 
with NASH (online supplemental figure S1A), namely tumour 
necrosis factor (TNF), interleukin- 1β (IL- 1β), NACHT, LRR and 
PYD domains- containing protein 3 (NLRP3), cluster of differen-
tiation (CD)38 and CD68 (figure 1C, online supplemental table 
S1). In contrast, no correlation was found between RIPK3 expres-
sion and arginase- 1 mRNA levels, a marker of anti- inflammatory 
macrophages (online supplemental table S1). Increased RIPK3 
expression in patients with NAFLD further correlated with colla-
gen1α1 (COL1α1) and transforming growth factor (TGF-β), as 
well as necroptosis- related factors MLKL and RIPK1 (figure 1C, 
online supplemental table S1). Noteworthy, RIPK3 expression 
was also positively correlated with caspase- 1 and NLRP3 gene 
expression in the liver, but not with caspase- 3 mRNA levels 
(online supplemental table S1), suggesting that RIPK3 is linked 
to inflammasome activation in NASH.
In cohort B, hepatic RIPK3 protein levels were increased 
in hepatocytes of patients with higher NAFLD activity score 
(NAS) and fibrosis scores (figure 1D, online supplemental figure 
S1B). Accordingly, RIPK3 positively and negatively correlated 
with circulating ferritin and platelet levels, respectively (online 
supplemental table S1), independent predictors of advanced 
fibrosis in NAFLD.23 24 In addition, hepatic RIPK3 positively 
correlated with circulating markers of liver injury before and 
1 year after bariatric surgery (figure 1E). Interestingly, male 
patients with NAFLD (online supplemental figure S1C) and 
carriers of the rs738409 GG genotype in patatin- like phosphate 
domain- containing protein 3 (PNPLA3) presented significantly 
higher hepatic RIPK3 levels compared with controls (figure 1D). 
In turn, no association was found between RIPK3 and the trans-
membrane 6 superfamily member 2 nor the membrane bound 
O- acyltransferase domain- containing 7 (data not shown). Finally, 
although NAFLD is strongly linked with metabolic syndrome, 
RIPK3 levels were not associated with diabetes mellitus (online 
supplemental figure S1D), arterial hypertension or dyslipidaemia 
(data not shown), neither correlated with circulating levels of 
lipids or glucose (online supplemental table S1).
Overall, the analysis of a large number of patients with 
NAFLD shows that hepatic RIPK3 mRNA and protein levels are 
increased in advanced disease, correlating with NASH develop-
ment, liver damage, fibrosis and inflammation.
RIPK3 deficiency ameliorates hepatic inflammation and 
fibrosis in CDAA diet-induced experimental NASH
Our data in human NAFLD cohorts strongly hinted that RIPK3- 
dependent signalling is involved in disease pathogenesis. To 
further dissect its contribution, we used a choline- deficient 
L- amino acid- defined (CDAA) diet model, mimicking both 
histological and pathophysiological features of NAFLD.25 26 An 
isocaloric choline- sufficient L- amino acid- defined (CSAA) diet 
was used as control.
Ripk3−/− mice aged 7–8 weeks displayed increased body 
weight gain over time compared with WT mice on both diets 
(figure 2A). Total food intake was similar between experi-
mental groups (online supplemental figure 2A). Although the 
relative increase in the liver- to- body weight ratio induced by 
the CDAA diet was similar between WT and Ripk3−/− mice, 
CSAA- fed Ripk3−/− mice exhibited hepatomegaly compared 
with CSAA- fed WT mice at 32 weeks (figure 2B). Further-
more, hepatic triglycerides (TG) and free fatty acids (FFA) were 
augmented in the liver of CDAA- fed animals, while FFA were 
also increased in CSAA- fed Ripk3−/− mice (online supplemental 
figure S2B). Accordingly, the steatosis score was augmented in 
Ripk3−/− mice compared with WT mice under the CSAA diet, 
without any histological evidence of inflammatory cell infiltra-
tion or hepatocyte injury (figure 2C, table 1). Intriguingly, serum 
FFA increased in CDAA- fed mice irrespective of genotype, while 
elevated TG were only found in Ripk3−/− mice, irrespective of 
diet (online supplemental figure S2B). Despite the lack of impact 
of Ripk3 deletion on CDAA- induced circulating levels of liver 
enzymes (data not shown), Ripk3 deficiency decreased the grade 
of inflammatory cell infiltration induced by the CDAA diet at 32 
weeks (figure 2C, table 1), as well as hepatic F4/80- positive cells 
and mRNA (figure 2D), and expression of pro- inflammatory 
markers Tnf-α, toll- like receptor 4 (Tlr4), Nlrp3 and cycloox-
ygenase 2 (Cox- 2) (figure 2E). Furthermore, although hepatic 
fibrosis was mild at 32 weeks (figure 2F, table 1), hydroxyproline 
quantification showed less hepatic collagen content in CDAA 
Ripk3−/− mice compared with WT mice (figure 2G).
Finally, similar to patients with NAFLD, liver RIPK3 levels 
were increased in WT mice fed the CDAA diet for 32 weeks, 
compared with the CSAA diet. MLKL phosphorylation was 
similarly increased but prevented by Ripk3 deletion (figure 2G). 
Altogether, targeting RIPK3 may halt NAFLD progression, at 
least in part, by preventing necro- inflammation associated with 
necroptotic cell death.
Absence of RIPK3 ameliorates disease severity induced by 
long-term CDAA feeding
Mice fed the CDAA diet for 66 weeks were used to evaluate 
the functional role of RIPK3- dependent signalling in NAFLD 
progression towards HCC. Much like at 32 weeks, Ripk3 defi-
ciency ameliorated the grade of inflammation but not liver- 
to- body weight ratio nor steatosis at 66 weeks (figure 3A,B, 
table 1, online supplemental figure S2B). In agreement with the 
reduction of inflammatory cell infiltration, F4/80 protein and 
mRNA levels (figure 3C) and expression of pro- inflammatory 
mediators Tnf-α, Tlr4, Nlpr3 and Cox- 2 were also decreased in 
CDAA- fed Ripk3−/− mice, compared with WT mice (figure 3D). 
Furthermore, the NAS score was significantly lower in Ripk3−/− 
than in WT mice, with Ripk3−/− mice exhibiting only border-
line NASH (NAS<5) (table 1). Histological examination also 
showed that CDAA diet promoted progressive pericellular and 
periportal hepatic fibrosis in WT mice, while Ripk3 deficiency 
significantly prevented the development of fibrosis in periportal 
spaces (figure 3E, table 1). Other histopathological abnormali-
ties commonly observed in NASH, such as Mallory- Denk bodies 
and ceroid- laden macrophages, were also detected in liver 
sections of WT mice fed the CDAA- fed mice, and decreased 
in CDAA Ripk3−/− mice (figure 3B, online supplemental figure 
S2C).
After 66 weeks of CDAA feeding, all mice developed macro-
scopic preneoplastic nodules (figure 3F), at a multiplicity of 
5.2±2.1 in WT and 3.9±0.8 in Ripk3−/− mice. In addition, 
one of seven mice in each WT and Ripk3−/− CDAA diet groups 
developed HCC (online supplemental figure S3A). Histological 
analysis of HCC tumours revealed a trabecular growth pattern 
and cytoplasmic inclusions (online supplemental figure S3B). 
Livers from CSAA diet- fed mice lacked tumours. Of note, Ripk3 
deficiency significantly reduced CDAA- induced hepatocyte 
proliferation in Ki67 immunohistochemistry (figure 3G). The 
reduction in the tumour burden provided by Ripk3 deletion was 
corroborated in established liver tumourigenesis induced by the 
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Figure 2 Absence of receptor- interacting protein kinase 3 (RIPK3) ameliorates hepatic inflammation and fibrosis during choline- deficient L- amino 
acid- defined diet (CDAA) diet- induced experimental non- alcoholic steatohepatitis (NASH). C57BL/6 wild- type (WT) or Ripk3−/− mice were fed a CDAA 
or an isocaloric control choline- sufficient L- amino acid- defined (CSAA) diet for 32 weeks. (A) Total body weight over time. (B) Liver- to- body weight 
ratio. (C) Representative images of H&E stained liver sections and immunoperoxidase staining for F4/80. Scale bar=100 µm. (D) Histograms show the 
quantification of F4/80- positive area (left) and F4/80 mRNA levels (right). (E) Quantitative RT- PCR analysis of Tnf-α, Tlr4, Nlrp3 and Cox- 2 in mouse 
liver. (F) Representative images of Masson’s trichrome stained liver sections. (G) Liver hydroxyproline content. (H) Immunoblotting and densitometry 
of RIPK3, p- mixed lineage kinase domain- like protein (p- MLKL) and MLKL. Blots of RIPK3 were normalised to endogenous β-actin, whereas p- MLKL 
was normalised to MLKL. Representative immunoblots are shown. Results are expressed as mean±SEM arbitrary units or fold change of six to seven 
individual mice. Scale bar=250 µm. §P<0.05 and *p<0.01 from CSAA- fed WT mice; †p<0.05 and ‡p<0.01 from CDAA- fed WT mice.
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chemical carcinogen diethylnitrosamine (DEN) (online supple-
mental figure S3C).
Importantly, in contrast with the 32 weeks time- point, CDAA 
feeding for 66 weeks reduced hepatic necroptosis, as seen by 
the significant downregulation of RIPK3 expression and MLKL 
phosphorylation in WT mice (figure 3H), suggesting that long- 
term CDAA feeding results in liver resistance to regulated cell 
death, contrasting with the active role of necroptosis in the 
pathogenesis of NAFLD.16 17
RIPK3 deficiency dampens signalling pathways involved in 
tumour development
For an unbiased analysis of liver carcinogenesis, we performed 
a comparative PCR array analysis of 84 genes associated with 
liver cancer progression in normal liver tissue (NT) or hepatic 
preneoplastic macroscopic nodules from WT and Ripk3−/− 
mice fed a CDAA diet for 66 weeks. The heatmap of differ-
entially expressed genes showed a distinct transcriptional 
profile between WT liver nodules and WT or Ripk3−/− NT or 
Ripk3−/− nodules (figure 4A,B, online supplemental table S4), 
corroborated by independent quantitative RT- PCR validation on 
randomly selected genes (Akt, Cdkn1a, Rac1 and Rhoa) (online 
supplemental figure S3D). Pathway enrichment analysis indi-
cated that genes associated with cancer, Wnt signalling pathways 
and oncogenes were upregulated in nodules of CDAA- fed WT 
mice, comparing with Ripk3−/− nodules (figure 4C). Indeed, the 
protein levels of the oncogene β-catenin (Ctnnb1) were only 
upregulated in WT nodules (figure 4D).
Gene Ontology process enrichment suggested that the absence 
of RIPK3 decreased cell proliferation and increased apoptosis in 
preneoplastic nodules (figure 4C). Indeed, caspase- 3/caspase- 7 
activity was decreased in preneoplastic nodules- enriched samples 
from WT mice compared with nodules from Ripk3−/− mice; 
caspase- 3/caspase- 7 activity was unaffected by CDAA feeding in 
Ripk3−/− mice (figure 4E). Furthermore, in CDAA- fed WT mice, 
cyclin D1 (Ccnd1) expression increased in nodules comparing 
with NT, while p53 (Tp53) and p21 (Cdkn1a) expressions 
were decreased. Strikingly, p21 was strongly increased in the 
liver of Ripk3−/− mice irrespective of the diet, while p53 and 
cyclin D1 expression in preneoplastic nodules was restored 
to basal levels by Ripk3 deficiency (figure 4D). Still, cellular 
senescence hallmarks such as β-galactosidase- positive cells and 
p16 expression were not differentially modulated in Ripk3−/− 
livers compared with WT mice (online supplemental figure 
3E,F). α-Fetoprotein (AFP) was also increased in both NT and 
preneoplastic nodules of CDAA- fed WT mice, but not in liver of 
Ripk3−/− mice (figure 5A). Protein levels of additional stemness- 
associated markers, including Nanog and aldehyde dehydro-
genase 1/2 (ALDH), were only upregulated in preneoplastic 
lesions of WT mice. Importantly, DNA damage sensor γH2AX 
expression was uniquely increased in preneoplastic lesions of 
WT nodules (figure 5A), whereas Ripk3 deficiency also abro-
gated CDAA- induced reactive oxygen species in the liver of mice 
fed a CDAA diet for 66 weeks (figure 5B). We have previously 
shown that absence of Ripk3 attenuates oxidative stress in exper-
imental NASH.16 Strikingly, the hepatic expression of α-smooth 
muscle actin, macrophage inflammatory protein 2 and vimentin, 
markers of epithelial- mesenchymal transition implicated in liver 
tumourigenesis and angiogenesis,27 were markedly increased in 
WT preneoplastic nodules, while the absence of Ripk3 prevented 
its upregulation in nodular lesions (figure 5C–D). Finally, CDAA- 
induced p38 phosphorylation in preneoplastic nodules was abro-
gated by Ripk3 deficiency (figure 5D) in agreement with reports 
that RIPK3 promotes vascular permeability through necroptotic- 
independent activation of p38.28 Taken together, these findings 
suggest that the absence of Ripk3 dampens signalling pathways 
implicated in transformation of dysplastic hepatocytes and 
aggressiveness of tumours.
Deletion of RIPK3 impacts on hepatic lipidome and 
upregulates PPARγ
Because alterations in liver fat accumulation and body weight 
were observed in Ripk3−/− mice, we next analysed the mouse 
hepatic lipidome at 32 weeks, the time- point where increased 
RIPK3 levels were observed in CDAA- fed WT mice. Univariate 
analysis and non- supervised principal components analysis of 
the lipidomics data evidenced the existence of metabolic clus-
ters associated with diet and mice genotype (figure 6A, online 
supplemental figure S4A). In particular, Ripk3 deficiency 
decreased levels of diglycerides (DG) and TG with longer acyl 
chains and high number of double bonds (figure 6B,C, online 
supplemental figure S4B). Furthermore, monounsaturated FA 
(MUFA) and polyunsaturated (PUFA)/saturated FA (SFA) or 
MUFA/PUFA ratios were decreased in CDAA- fed WT mice, but 
Table 1 Histological data of the CDAA murine model
Variable
32 weeks 66 weeks
CSAA CDAA CSAA CDAA
WT Ripk3−/− WT Ripk3−/− WT Ripk3−/− WT Ripk3−/−
Steatosis
(0–3)
0±0 1.7±0.§ 3±0* 3±0* 1.3±0.7 3±0§ 2.8±0.3§ 3±0§
Inflammation
(0–3)
0±0 0.3±0.3 2±0* 1±0.3§† 0±0 0±0 2.3±0.5* 0.8±0.3†
Ballooning
(0–2)
0±0 0±0 1±0* 1±0* 0±0 0.3±0.3 1±0* 1±0*
NAS
(0–8)
0±0 2±0.6 6±0* 5.3±0.3* 1.3±0.7 3.3±0.3 6.5±0.4* 4.7±0.3*†
Fibrosis
(0–4)
0±0 0±0 1±0* 1±0* 0±0 0.3±0.3 2±0* 1±0*†
Values are mean±SEM of four individual mice.
§P<0.05 from CSAA diet WT mice at respective time- point.
*P<0.01 from CSAA diet WT mice at respective time- point.
†P<0.05 from CDAA diet WT mice at respective time- point.
CDAA, choline- deficient L- amino acid; CSAA, choline- sufficient L- amino acid; NAS, NAFLD activity score; WT, wild- type.
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Figure 3 Absence of receptor- interacting protein kinase 3 (RIPK3) ameliorates disease severity induced by long- term choline- deficient L- amino 
acid (CDAA) feeding. C57BL/6 wild- type (WT) or Ripk3−/− mice were fed a CDAA or an isocaloric control choline- sufficient L- amino acid (CSAA) diet 
for 66 weeks. (A) Liver- to- body weight ratio. (B) Representative images of H&E stained liver sections and immunoperoxidase staining for F4/80. 
Scale bar=250 µm. (C) Histograms show the quantification of F4/80- positive area (left) and F4/80 mRNA levels (right). (D) Quantitative RT- PCR 
analysis of Tnf-α, Tlr4, Nlrp3 and Cox- 2 in mouse liver. (E) Representative images of Masson’s trichrome stained liver sections. Scale bar=250 µm. 
(F) Representative macroscopic pictures of livers. The scale bar represents 0.5 cm; arrowhead depicts preneoplastic nodules. (G) Representative 
immunoperoxidase staining for Ki67. Histogram show the quantification of Ki67- positive cells in percentage. Scale bar=100 µm. (H) Immunoblotting 
and densitometry of RIPK3, mixed lineage kinase domain- like protein (p- MLKL) and MLKL. Blots of RIPK3 were normalised to endogenous β-actin, 
whereas p- MLKL was normalised to MLKL. Representative immunoblots are shown. §P<0.05 and *p<0.01 from CSAA- fed WT mice; †p<0.05 from 
CDAA- fed WT mice.
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Figure 4 Receptor- interacting protein kinase 3 (RIPK3) deficiency impacts on transcriptional profiles associated with tumour development during 
long- term choline- deficient L- amino acid (CDAA) feeding. C57BL/6 wild- type (WT) or Ripk3−/− mice were fed a CDAA or an isocaloric control choline- 
sufficient L- amino acid (CSAA) diet for 66 weeks. (A) Heatmap of differentially expressed genes in NT from CDAA Ripk3−/− mice, nodules from CDAA 
WT and Ripk3−/− mice compared with NT from CDAA WT mice. The colour code represents the transformed ratios between means of the groups 
(log2(fold change)), where red indicates overexpressed transcripts and green represents underexpressed transcripts. (B) Venn diagrams showing the 
number of upregulated and downregulated transcripts. (C) Gene Ontology (GO) process, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
and oncogenes enrichment analysis for the differentially expressed genes in WT and Ripk3−/− nodules. The false discovery rate (FDR)- adjusted P value 
was indicated. (D) Immunoblotting and densitometry of β-catenin, p53, cyclin D1 and p21 in mouse liver. Blots were normalised to endogenous 
β-actin. Representative immunoblots are shown. (E) Caspase- 3/Caspase- 7 activity assay. Results are expressed as mean±SEM arbitrary units or fold 
change of six to seven individual mice. NT, non- tumorous tissue (tissue without macroscopic discernible nodules). §P<0.05 and *p<0.01 from CSAA- 
fed WT mice; †p<0.05 from and ‡p<0.01 from CDAA- fed WT mice. φP<0.01 from NT tissue of CDAA WT mice.
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increased in CDAA Ripk3−/− versus CDAA WT mice (table 2). 
Ripk3 deletion associated with increased FA 16:1n- 7/16:0 and FA 
18:1n- 9/18:0 ratios, irrespective of the diet (table 2), indicating 
increased stearoyl- CoA desaturase (SCD) activity in Ripk3−/− 
mice. Similarly, fatty acid desaturases appear to be modulated 
in Ripk3−/− mice fed the CDAA diet, as evidenced by the change 
in FA 18:3n- 6/18:2n- 6, 20:4n- 3/20:3n- 3 and 20:5n- 3/20:4n- 3 
ratios (table 2). In line with increased liver fat accumulation in 
CSAA Ripk3−/− mice, the FA 16:0/18:2n- 6 ratio, surrogate of 
lipogenic index, and fatty acid synthase (Fasn) and acetyl- CoA 
carboxylase mRNA levels were also increased (table 2, online 
supplemental figure S4C). Conversely, FA 22:5n- 3/20:5n- 3 and 
FA 18:0/16:0 ratios, indicative of elongation of very long chain 
fatty acid protein (ELOVL2/5) and ELOVL6 activities, respec-
tively, were not affected by Ripk3−/− deficiency. Of note, very 
long chain fatty acids have been functionally implicated in necro-
ptosis14 15; here, we show that Ripk3 deficiency could increase 
the expression of the first committed enzymes in the de novo 
lipogenesis pathway, but species with long acyl chains were even 
decreased in Ripk3−/− mice. In addition, very long- chain specific 
acyl- CoA dehydrogenase and medium- chain- specific acyl- CoA 
dehydrogenase that catalyse the first step of the mitochondrial 
fatty acid β-oxidation pathway were increased in CDAA- fed 
Ripk3−/− mice compared with WT counterparts. This is in agree-
ment with our previous observations showing that Ripk3−/− 
deficiency improves mitochondrial respiratory chain enzymatic 
complexes activity during CDAA feeding, while inhibition of the 
downstream target of RIPK3 increased β-oxidation on steatotic 
stimuli.13 Finally, TG/DG and omega- 6/omega- 3 ratios, which 
are increased in human NAFLD,29 were augmented in CDAA- fed 
Figure 5 Receptor- interacting protein kinase 3 (RIPK3) deficiency impacts on oxidative damage and signalling pathways interactions associated 
with cancer phenotypes. C57BL/6 wild- type (WT) or Ripk3−/− mice were fed a choline- deficient L- amino acid (CDAA) or an isocaloric control choline- 
sufficient L- amino acid (CSAA) diet for 66 weeks. (A) Immunoblotting and densitometry of α-fetoprotein (AFP), Nanog, aldehyde dehydrogenase 1/2 
(ALDH) and γH2AX in mouse liver. Blots were normalised to endogenous β-actin. Representative immunoblots are shown. (B) Fluorescence intensity 
from whole cells lysates stained with the fluorescence probe H2DCFDA. Values were normalised with total protein levels. (C) Quantitative RT- PCR 
analysis of α-smooth muscle actin (α-Sma) and macrophage inflammatory protein 2 (Mip- 2) in mouse liver. (D) Immunoblotting and densitometry 
of vimentin, p- p38 and p38. Blots of vimentin were normalised to endogenous β-actin, whereas p- p38 was normalised to p38. Representative 
immunoblots are shown. Results are expressed as mean±SEM fold change of six to seven individual mice. NT, non- tumorous tissue (tissue without 
macroscopic discernible nodules). §P<0.05 and *p<0.01 from CSAA- fed WT mice; †p<0.05 from and ‡p<0.01 from CDAA- fed WT mice. φP<0.01 from 
non- tumour tissue of CDAA WT mice. ROS, reactive oxygen species.
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Figure 6 Deletion of receptor- interacting protein kinase 3 (RIPK3) impacts on hepatic lipidome and upregulates peroxisome proliferator- activated 
receptor γ (PPARγ) in vivo. C57BL/6 wild- type (WT) or Ripk3−/− mice were fed a choline- deficient L- amino acid (CDAA) or an isocaloric control choline- 
sufficient L- amino acid (CSAA) diet for 32 weeks. (A) Score scatter plot corresponding to a principal components analysis (PCA) of the lipidomic 
data from hepatic tissue samples. Each individual is represented by one dot. (B) Relative intensity of two selected triglycerides (TG). (C) Heatmap 
representation of the TG number of carbons and double bond content in Ripk3−/− mice versus WT mice. The colour code represents the transformed 
ratios between means of the groups (log2(fold change)). *P<0.05, **p<0.01, p<0.001. (D) Serum fasting insulin and glucose levels from mice. (E) 
Glucose tolerance test of CSAA, CDAA or standard diet (SD)- fed mice. (F) Liver glycogen content. (G) Serum fibroblast growth factor- 21 (FGF- 21) from 
mouse. (F) Immunoblotting and densitometry of PPARγ in mouse liver. Blots were normalised to endogenous β-actin. Representative immunoblots 
are shown. Results are expressed as mean±SEM arbitrary units or fold change of six to seven individual mice. §P<0.05 and *p<0.01 from CSAA- 
fed WT mice; †p<0.05 from CDAA- fed WT mice. (G) Representative immunoblots of RIPK3 and PPARγ in the liver of patients from cohort A (n=22) 
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WT mice, a phenomenon that was prevented by Ripk3 deletion 
(table 2). Overall, Ripk3 deletion induced global changes in the 
hepatic lipidome of mice fed both the CSAA and CDAA diets at 
32 weeks, towards a better lipid profile in the context of NASH.
Since lipid metabolism, including FA desaturation, and 
insulin/glucose metabolism are closely interrelated,30 we also 
found that Ripk3−/− mice displayed increased fasting insulin 
irrespective of diet (figure 6D), without impacting on glucose 
tolerance (figure 6E) and even improving hepatic glycogen levels 
in CDAA- fed mice (figure 6F). Furthermore, serum levels of 
fibroblast growth factor- 21 (FGF- 21), a metabolic regulator of 
glucose and lipid metabolism, increased in Ripk3−/− mice irre-
spective of diet (figure 6G).
The phenotypic and metabolic changes found in Ripk3−/− mice 
fed either a CSAA or CDAA diet, namely reduced inflamma-
tion, less cell proliferation and augmented body weight, hepatic 
lipid storage, SCD activity and insulin, prompted us to inves-
tigate the regulation of PPARγ by RIPK3. We found increased 
PPARγ protein and mRNA levels in the liver of Ripk3−/− mice 
(figure 6H, online supplemental figure S4E). Moreover, in 
the liver of patients from NAFLD cohort A, PPARγ negatively 
correlated with RIPK3 (figure 6I). In agreement, on treatment 
with palmitic acid (PA), Ripk3−/− primary hepatocytes displayed 
increased Pparγ promoter activity and mRNA levels compared 
with WT hepatocytes (online supplemental figure S5A and B). 
Furthermore, in Ripk3−/− primary hepatocytes, PA- induced Fasn 
expression and intracellular fat accumulation as assessed by Nile 
red fluorometric quantification were, at least in part, PPARγ-de-
pendent (online supplemental figure S5B and C). Knockdown of 
RIPK3 was also associated with decreased levels of collagen and 
vimentin in immortalised human hepatic stellate cells LX- 2 after 
TGF-β treatment, while co- silencing of PPARγ abrogated this 
phenotype (online supplemental figure S5D and E), suggesting 
that increased PPARγ levels in Ripk3 cells also contributes to 
impaired fibrosis development.
Also, in line with increased FGF- 21 levels, Pparγ mRNA was 
upregulated in white adipose tissue of CDAA- fed Ripk3−/− mice, 
accompanied by increased expression of uncoupling protein 1, 
a target of PPARγ involved in thermogenesis (online supple-
mental figure S3E). Circulating levels of leptin, an adipokine 
that reflects adipose tissue mass, regulates energy homeostasis 
and whose expression is controlled by PPARγ, diminished on 
CDAA feeding in WT mice, whereas deletion of Ripk3−/− raised 
leptin levels compared with their WT CSAA or CDAA- fed coun-
terparts (online supplemental figure S4G). Conversely, the diet 
or genotype did not impact on mouse serum adiponectin levels. 
The white adipose tissue preserved the normal architecture 
with well- differentiated adipocytes. However, the infiltration of 
Table 2 Relative hepatic lipid content of the study groups from the CDAA murine model at 32 weeks
Parameter
CDAA WT vs CSAA WT CDAA Ripk3−/− vs CDAA WT CSAA Ripk3−/− vs CSAA WT CDAA Ripk3−/− vs CSAA Ripk3−/−
Fold change P value Fold change P value Fold change P value Fold change P value
FA 1.09 ns 1.05 ns 0.85 ns 1.34 0.04
SFA 1.22 ns 0.95 ns 0.80 0.06 1.45 0.01
MUFA 0.92 ns 1.22 ns 0.98 ns 1.14 ns
PUFA 1.12 ns 1.02 ns 0.81 ns 1.41 0.03
FA omega- 3 1.06 ns 1.06 ns 0.74 0.03 1.52 0.01
FA omega- 6 1.20 ns 1.90 ns 0.75 0.08 1.43 0.03
FA omega- 9 0.90 ns 1.22 ns 1.08 ns 1.01 ns
DG 1.08 ns 1.42 <0.001 1.41 0.05 1.09 ns
Saturated DG 1.16 ns 1.69 <0.001 1.93 0.02 1.02 ns
TG 1.57 0.01 1.18 ns 1.13 ns 1.64 <0.001
Saturated TG 1.71 0.01 1.34 ns 1.57 0.01 1.46 0.04
ChoE 1.13 ns 1.27 ns 1.04 ns 1.37 0.02
PC 0.94 ns 0.92 ns 0.78 <0.001 1.10 ns
PE 1.42 0.01 0.91 ns 0.80 <0.001 1.62 0.001
Cer 1.01 ns 1.06 ns 0.83 0.04 1.27 0.01
SM 1.06 ns 0.96 ns 0.73 0.001 1.39 <0.001
MUFA+PUFA/SFA 0.86 0.04 1.14 0.03 1.08 ns 0.91 ns
PUFA/MUFA 1.22 0.04 0.80 0.03 0.81 0.02 1.20 0.03
Omega- 6/omega- 3 1.19 0.04 0.81 0.03 1.03 ns 0.94 ns
TG/DG 1.42 0.001 0.84 0.04 0.83 0.07 1.45 0.001
SM+DG/Cer+PC 1.12 0.01 1.19 0.001 1.21 0.01 1.10 ns
FA 16:0/18:2n- 6 1.06 ns 0.99 ns 1.18 0.04 0.90 ns
FA 16:1n- 7/16:0 0.58 ns 2.39 <0.001 1.72 0.01 0.94 ns
FA 18:0/16:0 1.14 ns 0.78 ns 0.97 ns 0.92 ns
FA 18:1n- 9/18:0 0.77 ns 1.54 0.01 1.16 ns 1.02 ns
FA 18:3n- 6/18:2n- 6 1.66 <0.001 0.78 <0.01 1.03 ns 1.25 0.01
FA 20:4n- 3/20:3n- 3 0.69 0.001 1.50 <0.001 1.01 ns 1.02 ns
FA 20:5n- 3/20:4n- 3 1.56 0.01 0.71 0.02 0.93 ns 1.20 ns
FA 22:5n- 3/20:5n- 3 1.48 <0.01 0.87 ns 1.00 ns 1.28 <0.01
Cer, ceramides; ChoE, cholesteryl esters; DG, diglycerides; FA, fatty acids; MUFA, monounsaturated fatty acids; ns, non- significant; PC, phosphatidylcholines; PE, 
phosphatidylethanolamines; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; SM, sphingomyelins; TG, triglycerides.  on D
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mononuclear inflammatory cells, such as macrophages and occa-
sional lymphocytes, was increased in CSAA- fed Ripk3−/− mice 
(online supplemental figure S4H), possibly as a side effect of 
augmented leptin levels from the baseline.
These results suggest that RIPK3 plays an intricate role in 
regulating metabolism, likely through PPARγ targeting, in 
parallel with its role in necroptosis.
DISCUSSION
Despite several ongoing clinical trials, no effective pharma-
cological approach against NASH- induced fibrosis and HCC 
has yet been approved, pointing the need for a better under-
standing of pathogenic mechanisms underpinning NAFLD. The 
present study provides evidence that RIPK3- dependent necro-
ptosis plays a determinant role in the pathogenesis and progres-
sion of NAFLD, facilitating fibrosis development and cancer 
initiation. We show increased RIPK3 levels in serum and liver 
of patients with NAFLD that correlate with disease severity, 
including markers of liver damage, inflammation and fibrosis. 
Furthermore, liver RIPK3 levels prior to bariatric surgery also 
positively correlated with increased circulating markers of liver 
injury 1 year after surgery. Interestingly, hepatic levels of RIPK3 
were increased in male patients with NAFLD and carriers of 
the rs738409 C>G variant in the PNPLA3 gene, well- known 
risk factors of NAFLD, advanced fibrosis and HCC.3 31 In sum, 
augmented hepatic RIPK3 levels associate with key genetic and 
phenotypic determinants of NAFLD progression, emphasising 
the role of RIPK3- dependent necroptosis in regulating NAFLD 
pathogenesis.
We show that the association between RIPK3 and inflamma-
tion/fibrosis in human NAFLD is back translated in the CDAA 
murine model. Indeed, our results demonstrate that RIPK3 
deficiency prevents hepatic inflammation, while reducing liver 
fibrosis, in response to CDAA feeding for both 32 and 66 weeks. 
Most cancers likely result from a cooperation between (micro)
environmental factors and genetic somatic mutations, with the 
link between cancer and inflammation/fibrosis being well estab-
lished in HCC. Indeed, pro- inflammatory TNF-α has been 
implicated in tumour growth and poor prognosis of HCC, at 
least in part, by activating tumour progenitor cells.32 Similarly, 
COX- 2 overexpression in hepatocytes has been shown to induce 
spontaneous HCC development in mice,33 likely through modu-
lation of progenitor/stem Wnt/β-catenin signalling pathways.34 
In this regard, we show that CDAA- fed Ripk3−/− mice display 
reduced hepatic expression of Tnf-α and Cox- 2, accompanied 
by decreased protein levels of β-catenin, AFP and other markers 
of stemness. Our results further demonstrate that long- term 
CDAA feeding dampens p53- dependent signalling pathway in 
WT preneoplastic nodules, alongside increased compensatory 
hepatocyte proliferation, which were restored by Ripk3 defi-
ciency. Taken together, our results suggest that deletion of Ripk3 
associates with a better prognosis, at least in part, by reducing the 
inflammatory milieu that favours survival of dysplastic hepato-
cytes. Still, the inflammatory role of RIPK3- dependent signalling 
could play an intricate, cell/context- dependent role in hepatocar-
cinogenesis in vivo. On one hand, it was recently reported that 
RIPK3 deficiency exacerbates DEN plus CDAA- induced HCC in 
mice by promoting an immunosuppressive microenvironment,35 
while here we showed that Ripk3−/− mice were protected from 
tumour burden induced by both CDAA or DEN. On the other, 
it was recently shown that the necroptosis- associated hepatic 
cytokine microenvironment could govern cholangiocarcinoma 
development from ontogenically transformed hepatocytes.11 
However, further studies are needed to corroborate this hypoth-
esis in the context of NAFLD progression towards liver cancer. 
Emerging evidence has shown that RIPK3- dependent signal-
ling could also play a pivotal role in metabolic reprograming 
in vitro,12 14 15 but its contribution to metabolic liver disease 
remains to be elucidated. Inflammation may sometimes precede 
steatosis in human NAFLD, while only 10%–20% of patients 
with simple steatosis advance towards inflammatory and fibrotic 
stages,36 suggesting that liver steatosis and inflammation consti-
tute independent events. Indeed, although expression of PPARγ 
in the normal liver is very low, Pparγ deletion in hepatocytes 
was shown to ameliorate liver steatosis but increase inflamma-
tion in mice on HFD‐plus‐binge ethanol.37 Noteworthy, both 
the CSAA and CDAA diets (~4.4 kcal/g) contain higher calo-
ries than a standard chow (~3 kcal/g).38 Thus, our results show 
that Ripk3−/− mice under the hypercaloric CSAA diet display 
increased hepatic lipogenesis and fat accumulation in the 
absence of liver inflammation, together with increased hepatic 
expression of PPARγ. Noteworthy, PPARγ agonists, which 
induce moderate weight gain, are used off- label in patients 
with NASH39 and may also impact on the hepatic lipidome by 
inducing SCD1,40 a desaturase implicated in the conversion of 
SFA to MUFA. Accordingly, Ripk3−/− mice fed either a CSAA 
or a CDAA diet were more obese than their WT counterparts, 
but display augmented MUFA+PUFA/SFA. Thus, our results 
support that, by upregulating PPARγ, Ripk3 deletion shifts the 
hepatic lipid profile to buffer the accumulation of detrimental 
lipid species and could trigger lipoexpediency, a phenomenon 
in which lipid signals generated by de novo lipogenesis can be 
directed towards benefit.41 Besides its well- known metabolic 
and anti- inflammatory effects, PPARγ also displays antiprolifer-
ative properties. For instance, PPARγ ligands have been shown 
to upregulate p21 and reduce cyclin D1 gene expression, inhib-
iting human lung carcinoma cell growth.42 Of note, in our study, 
Ripk3−/− mice at 66 weeks of CDAA feeding show a similar 
pattern. PPARγ has been suggested to act as a tumour suppressor 
in HCC,43 whereby its activation could contribute to arrest 
carcinogenesis in Ripk3−/− mice- fed a CDAA diet. Finally, in line 
with the reported antifibrogenic role of PPARγ activation,44 our 
results suggest that the upregulation of PPARγ in Ripk3- deficient 
hepatic stellate cells prevented collagen production and, thus, 
could contribute to impaired fibrosis development in CDAA- fed 
Ripk3−/− mice.
In agreement with our results, it was shown that HFD- fed 
Ripk3−/− mice also become obese and display increased liver 
steatosis compared with WT counterparts, and display augmented 
fasting insulin and glucose levels compared with chow diet- fed 
Ripk3−/− mice. In addition, PPARγ and SCD were also upregu-
lated in HFD- fed Ripk3−/− mice.18 However, in contrast with 
our results, inflammation and fibrosis were aggravated, likely 
due to increased apoptosis in the liver and adipose tissue.18 19 
The different outcomes of Ripk3 deletion in liver inflamma-
tion and fibrosis on different NAFLD models may rely on the 
specific features of each experimental model; the methionine- 
deficient and choline- deficient and CDAA diets cause substantial 
steatosis, inflammation, fibrosis and liver damage, whereas the 
HFD results solely in mild fibrosis and no liver damage, despite 
inducing steatosis.45 As such, although liver necroptosis is also 
activated in response to a HFD,18 its extent and relevance in 
these conditions is likely minor.
Whether PPARγ-related effects are solely a consequence of the 
genetic deletion of Ripk3 in mice under a hypercaloric diet, or 
whether they could also be achieved with the pharmacological 
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inhibition of core components of the necroptotic machinery, 
including RIPK3, remains unknown. Further insights on possible 
metabolic events resulting from the pharmacological inhibition 
of necroptosis should also be provided by the first clinical trials 
using a small molecule inhibitor of RIPK1 kinase for autoim-
mune diseases.46
In conclusion, our study provides a comprehensive character-
isation of the role of RIPK3- dependent signalling in a stepwise 
progression of NASH towards HCC, unravelling a paradoxical 
new role. While RIPK3 deficiency increases obesity, liver fat 
accumulation and insulin/glucose levels, it also impairs long- term 
inflammation and signalling pathways implicated in transforma-
tion of dysplastic hepatocytes. Thus, RIPK3 plays an intricate 
role in the interplay between cellular metabolism, cell death 
and inflammation, whose modulation could offer new venues to 
arrest NASH progression to HCC.
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